Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

GC012F · AZD0120

Cell therapy (CAR-T) · Kills target cells, directed at BCMA (TNFRSF17) and CD19 · developed by ASTRAZENECA

Phase 3 Most advanced trial

AZN Developer

1 Registered trials

What is GC012F?

GC012F is an autologous CAR-T cell therapy engineered to express two chimeric antigen receptors targeting BCMA and CD19, tumor-associated antigens on B-cell malignancies. The cells are manufactured using the FasT CAR-T platform, enabling production within 24 hours. It is studied in relapsed/refractory multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD0120
Drug type: Cell therapy (CAR-T)
Targets: BCMA (TNFRSF17) (antigen), CD19 (antigen)
Mechanism: Kills target cells, directed at BCMA (TNFRSF17) and CD19
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07391657	Phase 3	Relapsed Refractory Multiple Myeloma	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed Refractory Multiple Myeloma

Other drugs acting on TNFRSF17 / CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3 SEA-BCMA Phase 1

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind GC012F

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z